peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

protease inhibitor peptide

Elafin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Pharmacokinetics

The abstract reports key analytical sensitivity thresholds (blank, detection, and quantification limits) for the plasma Elafin CLIA method.

Sources[2]pubmedA Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment.including the limit of blank (LoB) (0.069 ng mL-1), limit of detection (LoD) (0.099 ng mL-1), limit of quantification (LoQ) (0.8 ng mL-1)
Reported result
LoB 0.069 ng mL-1; LoD 0.099 ng mL-1; LoQ 0.8 ng mL-1
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “including the limit of blank (LoB) (0.069 ng mL-1), limit of detection (LoD) (0.099 ng mL-1), limit of quantification (LoQ) (0.8 ng mL-1)”

    A Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment. · Abstract

    pubmed:41028930:446c00ca8b3f:446c00ca8b3f

Pharmacokinetics

The study collected trough (pre-dose) pharmacokinetic measurements over a 29-day follow-up period.

Sources[1]pubmedTiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial.Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days.”

    Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial. · METHODS

    pubmed:40956387:af6c1192b0fd:af6c1192b0fd

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, identity, interaction, mechanism, regulatory, safety
  • 116 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (100), assurance_score_below_0.72 (12), current_regulatory_source_required (8), extraction_ambiguity (100), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (14), no_direct_support (111), proposal_not_staged (1)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial. ↗

    pubmed · published 2025-11-01 · retrieved 2026-09-03T08:51:04Z

  2. A Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment. ↗

    pubmed · published 2025-12-01 · retrieved 2026-09-03T08:51:04Z

Publication history and provenance

Version 1 · Automated assessment · 2026-09-03T08:51:04Z

505a38c35121c7261767da794270525e9deef0bb14302df876f4dbcb946d13be